SPERO THERAPEUTICS INC (SPRO) Stock Overview
USA - NASDAQ:SPRO - US84833T1034 - Common Stock
SPRO Key Statistics, Chart & Performance
The current stock price of SPRO is 2.21 USD. In the past month the price increased by 16.93%. In the past year, price increased by 66.17%.
SPRO Latest News, Press Relases and Analysis
SPRO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.53 | 402.76B | ||
| AMGN | AMGEN INC | 13.38 | 157.07B | ||
| GILD | GILEAD SCIENCES INC | 15.63 | 150.06B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.88 | 108.04B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.66 | 61.26B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 60.75B | ||
| ARGX | ARGENX SE - ADR | 88.74 | 50.32B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.02 | 34.14B | ||
| INSM | INSMED INC | N/A | 33.75B | ||
| NTRA | NATERA INC | N/A | 26.42B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.40B | ||
| BIIB | BIOGEN INC | 9.36 | 21.98B |
Related stock screener links
About SPRO
Company Profile
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing treatments involving bacterial infections, including multi-drug resistant bacterial infections, and rare diseases Its pipeline product candidates include Tebipenem HBr, SPR720, and SPR206. The company is headquartered in Cambridge, Massachusetts and currently employs 32 full-time employees. The company went IPO on 2017-11-02. The firm is focused on identifying and developing novel treatments for rare diseases and diseases caused by multi-drug resistant (MDR) bacterial infections with unmet need. Its product candidate SPR720 is an investigational, chemically stable phosphate ester prodrug that is converted in vivo to SPR719 for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease. Its clinical stage product candidate, tebipenem HBr is an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP) to help patients potentially reduce duration of in-patient therapy.
Company Info
SPERO THERAPEUTICS INC
675 Massachusetts Ave Ste 14
Cambridge MASSACHUSETTS 02139 US
CEO: Ankit Mahadevia
Employees: 32
Phone: 18572421600
SPERO THERAPEUTICS INC / SPRO FAQ
What does SPERO THERAPEUTICS INC do?
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing treatments involving bacterial infections, including multi-drug resistant bacterial infections, and rare diseases Its pipeline product candidates include Tebipenem HBr, SPR720, and SPR206. The company is headquartered in Cambridge, Massachusetts and currently employs 32 full-time employees. The company went IPO on 2017-11-02. The firm is focused on identifying and developing novel treatments for rare diseases and diseases caused by multi-drug resistant (MDR) bacterial infections with unmet need. Its product candidate SPR720 is an investigational, chemically stable phosphate ester prodrug that is converted in vivo to SPR719 for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease. Its clinical stage product candidate, tebipenem HBr is an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP) to help patients potentially reduce duration of in-patient therapy.
What is the stock price of SPERO THERAPEUTICS INC today?
The current stock price of SPRO is 2.21 USD. The price increased by 0.45% in the last trading session.
Does SPRO stock pay dividends?
SPRO does not pay a dividend.
What is the ChartMill technical and fundamental rating of SPRO stock?
SPRO has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the sector and industry classification for SPERO THERAPEUTICS INC?
SPERO THERAPEUTICS INC (SPRO) operates in the Health Care sector and the Biotechnology industry.
What is SPERO THERAPEUTICS INC worth?
SPERO THERAPEUTICS INC (SPRO) has a market capitalization of 124.38M USD. This makes SPRO a Micro Cap stock.
When does SPERO THERAPEUTICS INC (SPRO) report earnings?
SPERO THERAPEUTICS INC (SPRO) will report earnings on 2025-11-12, after the market close.
SPRO Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to SPRO. When comparing the yearly performance of all stocks, SPRO is one of the better performing stocks in the market, outperforming 86.41% of all stocks.
SPRO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to SPRO. The financial health of SPRO is average, but there are quite some concerns on its profitability.
SPRO Financial Highlights
Over the last trailing twelve months SPRO reported a non-GAAP Earnings per Share(EPS) of -0.98. The EPS decreased by -327.91% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -86.29% | ||
| ROE | -163.28% | ||
| Debt/Equity | 0 |
SPRO Forecast & Estimates
7 analysts have analysed SPRO and the average price target is 5.1 USD. This implies a price increase of 130.77% is expected in the next year compared to the current price of 2.21.
For the next year, analysts expect an EPS growth of 33.34% and a revenue growth -48.42% for SPRO